Log in

Relevant bibliographies by topics / Prostate cancer and multiple myeloma / Journal articles

To see the other types of publications on this topic, follow the link: Prostate cancer and multiple myeloma.

Journal articles on the topic 'Prostate cancer and multiple myeloma'

Author: Grafiati

Published: 5 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prostate cancer and multiple myeloma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kmetec, Andrej, and Tine Hajdinjak. "Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid." Radiology and Oncology 47, no. 3 (2013): 289–95. http://dx.doi.org/10.2478/raon-2013-0041.

Full text

Abstract:

Abstract Background. The aim of the study was evaluation of zoledronic acid with regard to safety, effect on analgesic consumption and impact on occurrence of skeletal related events in patients with bone lesions from solid tumors and multiple myeloma. Methods. We conducted an observational, 12-month, phase IV and multi-center study. One hundred and twentyfive symptomatic (pain) bone-metastatic patients were included between 2007 and 2009: 92 prostate cancers, 28 multiple myelomas, 5 others. They were prescribed monthly infusions of zoledronic acid in accordance to each disease’s treatment gui

APA, Harvard, Vancouver, ISO, and other styles

2

Devaraj, Akshitha, and Hassen Al-Sader. "Osteolytic lesions: Multiple myeloma or prostate cancer?" Radiology Case Reports 18, no. 4 (2023): 1485–89. http://dx.doi.org/10.1016/j.radcr.2023.01.054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Beltran, Brady, Luis Riva, Daniel del Carpio, et al. "Osteonecrosis of the Jaw Related to Bisphosphonates Therapy in Multiple Myeloma and Metastatic Prostate Cancer Patients. A Latin American Report: An Adverse Event To Look For!!." Blood 110, no. 11 (2007): 5162. http://dx.doi.org/10.1182/blood.v110.11.5162.5162.

Full text

Abstract:

Abstract Background: Association between osteonecrosis of the jaw (ONJ) and aminobisphosphonate treatment in patients (pts.) with multiple myeloma, breast cancer and prostate cancer has been increasingly reported in the literature. Risk factors for this complication include presence of infection, recent dental extraction and any oral surgical procedure with bone exposure. Patients and Methods: All patients with myeloma multiple or prostate cancer diagnosis treated at two institutions from Lima with either IV zoledronic acid or pamidronate from 2005–2007 were evaluated using outpatient records.

APA, Harvard, Vancouver, ISO, and other styles

4

Hidajat, Mira, Damien Martin McElvenny, Peter Ritchie, et al. "Lifetime exposure to rubber dusts, fumes and N-nitrosamines and cancer mortality in a cohort of British rubber workers with 49 years follow-up." Occupational and Environmental Medicine 76, no. 4 (2019): 250–58. http://dx.doi.org/10.1136/oemed-2018-105181.

Full text

Abstract:

ObjectivesTo quantitatively evaluate exposure-response associations between occupational exposures to rubber dust, fumes and N-nitrosamines and cancer mortality in the UK rubber industry.MethodsCompeting risk survival analyses were used to examine cancer mortality risk in a cohort of 36 441 males aged 35+ years employed in the British rubber industry in 1967, followed up to 2015 (94% mortality). Exposure measurements are based on a population-specific quantitative job-exposure matrix for rubber dust, rubber fumes and N-nitrosamines from the EU-EXASRUB project.ResultsExposure (lifetime cumulati

APA, Harvard, Vancouver, ISO, and other styles

5

Kim, Nae Yu, Soo Jung Gong, Jimyung Kim, Seon Min Youn, and Jung-Ae Lee. "Multiple Myeloma with Biclonal Gammopathy Accompanied by Prostate Cancer." Annals of Laboratory Medicine 31, no. 4 (2011): 285–89. http://dx.doi.org/10.3343/kjlm.2011.31.4.285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kähkönen, Tiina E., Jie Wen, Ru Yang, Yuyang Xu, Michael Zhang, and Jussi M. Halleen. "Abstract 3927: Bone Metastasis Technology Platform: Establishing clinically relevant bone metastasis models for breast and prostate cancer and multiple myeloma." Cancer Research 85, no. 8_Supplement_1 (2025): 3927. https://doi.org/10.1158/1538-7445.am2025-3927.

Full text

Abstract:

Bone metastases are a significant clinical problem in many major cancers, especially in breast and prostate cancer where 70-90% of advanced patients develop bone metastases. Myeloma bone disease is associated with similar clinical problems than bone metastases, including increased risk of fractures and bone pain that decrease the quality of life. Current cancer therapies can only partially decrease tumor growth, resulting in only 5% of bone metastatic patients being alive 5 years after the diagnosis. Bone metastases are therefore a high unmet medical need with a high demand for effective thera

APA, Harvard, Vancouver, ISO, and other styles

7

Campagnaro, Erica, Melissa A. Reimers, Angel Qin, Ajjai S. Alva, Bryan J. Schneider, and Catherine H. Van Poznak. "Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice." Journal of Oncology Practice 14, no. 8 (2018): 457–64. http://dx.doi.org/10.1200/jop.18.00236.

Full text

Abstract:

The management of bone lesions from advanced solid tumors and multiple myeloma typically includes use of a bone-modifying agent to reduce the risk of skeletal-related events. Recent data demonstrate that when using zoledronic acid to reduce the risk of skeletal-related events in metastatic breast cancer, metastatic prostate cancer, and multiple myeloma, the dosing interval of zoledronic acid may be extended from every 4 weeks to every 12 weeks. The ASCO guidelines on the role of bone-modifying agents in metastatic breast cancer and multiple myeloma address zoledronic acid dosing intervals. Her

APA, Harvard, Vancouver, ISO, and other styles

8

Henegan, John Clark. "Concordance in the relative mortality rates for prostate cancer and gastric cancer in African Americans." Journal of Clinical Oncology 35, no. 6_suppl (2017): 270. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.270.

Full text

Abstract:

270 Background: The racial disparity in outcomes for prostate cancer, gastric cancer, and multiple myeloma is demonstrated by these malignancies having the highest age-adjusted mortality rate ratio for black Americans versus white Americans. A variety of factors have been identified as contributing to this disparity, leading to our hypothesis that there would not be concordance, in respect to the mean, when the county-level age-adjusted black: white mortality rate ratio for a malignancy was compared to the other two malignancies. Methods: Publically available information from cancerrates.gov w

APA, Harvard, Vancouver, ISO, and other styles

9

Holecki, Michał, Anna Skorupa, Jan Duława, and Jerzy Chudek. "Hypercalcemia in Patients Treated with Oral Bisphosphonates for Tumor-Induced Osteolysis." Open Access Macedonian Journal of Medical Sciences 1, no. 1 (2013): 54–58. http://dx.doi.org/10.3889/oamjms.2013.011.

Full text

Abstract:

Objective: Hypercalcemia as the consequence of an excessive bone resorption is a common complication in patients with cancer. The aim of the study was to analyze the prevalence of hypercalcemia in patients with tumor-induced osteolysis starting therapy with bisphosphonates.Methods: The questionnaire-based survey (data collected during three consecutive examinations within a 3-month period) was conducted among 1,450 patients treated with bisphosphonates for tumor-induced osteolysis.Results: Hypercalcemia was found in 8.7% respondents starting the treatment with bisphosphonates. The most common

APA, Harvard, Vancouver, ISO, and other styles

10

Kao, Johnny, Ashesh B. Jani, and Srinivasan Vijayakumar. "Is there an association between multiple myeloma and prostate cancer?" Medical Hypotheses 63, no. 2 (2004): 226–31. http://dx.doi.org/10.1016/j.mehy.2003.10.029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Mathur, Pankaj, Daisy Alapat, Manoj Kumar, and Sharmilan Thanendrarajan. "Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma." Clinical Case Reports 6, no. 2 (2017): 269–73. http://dx.doi.org/10.1002/ccr3.1308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kaltschmidt, Christian, Constanze Banz-Jansen, Tahar Benhidjeb та ін. "A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells". Cancers 11, № 5 (2019): 655. http://dx.doi.org/10.3390/cancers11050655.

Full text

Abstract:

Cancer stem cells (CSCs) account for tumor initiation, invasiveness, metastasis, and recurrence in a broad range of human cancers. Although being a key player in cancer development and progression by stimulating proliferation and metastasis and preventing apoptosis, the role of the transcription factor NF-κB in cancer stem cells is still underestimated. In the present review, we will evaluate the role of NF-κB in CSCs of glioblastoma multiforme, ovarian cancer, multiple myeloma, lung cancer, colon cancer, prostate cancer, as well as cancer of the bone. Next to summarizing current knowledge reg

APA, Harvard, Vancouver, ISO, and other styles

13

Lee, Jihyun, Hoin Kang, Soee Kim, Ju Bi Lee, Min-Ji Song, and Jung Won Kim. "Abstract 1990: New diagnostic technology to detect myeloma cells in the blood of multiple myeloma patients." Cancer Research 85, no. 8_Supplement_1 (2025): 1990. https://doi.org/10.1158/1538-7445.am2025-1990.

Full text

Abstract:

Abstract Introduction: Androgen-receptor splice variant 7 (AR-V7) is constitutively activated isoform of AR and has been associated with the resistance towards AR targeting therapies and development into metastatic castration-resistant prostate cancer (mCRPC). Analysis of AR-V7 expression is an important step in prostate cancer diagnosis and determining the therapeutic drug, but the detection of AR-V7 with tissues has limitations such as clinical challenge to poorly accessible tumor tissues before and after treatment. Here, we developed the method of AR-V7 detection in circulating tumor cells

APA, Harvard, Vancouver, ISO, and other styles

14

Talamo, Giampaolo, W. Christopher Ehmann, Nathan G. Dolloff, Jozef Malysz, Joseph J. Drabick, and Witold B. Rybka. "Retrospective analysis of second malignancies in patients with multiple myeloma." Journal of Clinical Oncology 30, no. 15_suppl (2012): 8090. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8090.

Full text

Abstract:

8090 Background: Recent data from patients with multiple myeloma (MM) enrolled in randomized clinical trials have shown an increased incidence of second malignancies after treatment with lenalidomide, but the prevalence of second malignancies in the overall MM population is uncertain. Methods: We retrospectively analyzed the medical records of 320 consecutive MM patients followed at the Penn State Hershey Cancer Institute between 2006 and 2010. We excluded from the analysis basocellular and squamocellular carcinomas of the skin. Results: Forty-three patients (13%) were found to have second mal

APA, Harvard, Vancouver, ISO, and other styles

15

Standridge, Meaghan, Shreya Desai, Sujith Abbagoni, et al. "Therapy Related Multiple Myeloma: A Distinct Entity." Blood 142, Supplement 1 (2023): 6657. http://dx.doi.org/10.1182/blood-2023-190298.

Full text

Abstract:

Background The development of therapy-related multiple myeloma (t-MM) is a poorly described entity. Multiple myeloma (MM) is the second most common hematologic malignancy. Despite significant strides in MM treatment over recent decades, identifying modifiable risk factors, optimizing screening methodologies, and identifying potential treatment strategies or targets to address t-MM remains of utmost importance, as this disease continues to pose a significant therapeutic challenge and remains incurable. This retrospective review seeks to explore the incidence and characteristics of t-MM at a med

APA, Harvard, Vancouver, ISO, and other styles

16

Buevich, E. I., Elena F. Kotovshchikova, A. F. Lazarev, and D. I. Ganov. "MULTIPLE PRIMARY TUMORS IN CHRONIC LEUKEMIA AND GENERALIZED LYMPHOMAS." Russian Journal of Oncology 23, no. 2 (2018): 79–81. http://dx.doi.org/10.18821/1028-9984-2018-23-2-79-81.

Full text

Abstract:

There are presented results of the analysis of case histories of 418 patients with generalized lymphomas and chronic leukemia, among whom 49 patients had information about multiple primary cancers. Among these patients, 37 were diagnosed as generalized lymphoma, 8 - multiple myeloma and 4 - chronic myelomonocytic leukemia. Most often hemoblastosis combined with skin cancer (17 patients), bowel cancer (11 patients) and lung cancer (9 patients). 3 patients had hemoblastosis combination with prostate, as well as kidney, stomach, and thyroid malignant diseases. Among all cases, 44 patients had two

APA, Harvard, Vancouver, ISO, and other styles

17

Pacheco-Feijoó, Gloria, Luis Podestá-Gavilano, Katherin Quevedo-Porras, and José Amado-Tineo. "Factors associated with quality of life in cancer patients in a social security pain therapy unit - Lima, Peru." Revista de la Facultad de Medicina Humana 23, no. 2 (2023): 62–70. http://dx.doi.org/10.25176/rfmh.v23i2.5649.

Full text

Abstract:

Introduction: Quality of life is one of the main concerns for cancer patients in palliative care; however, studies on quality of life in these patients are limited. Objective: To determine the factors associated with quality of life in patients with oncological disease in palliative care. Methods: Observational, analytical study in 184 cancer patients treated in a Pain and Palliative Care Unit during 2021. The dependent variable was quality of life; independent variables were age, sex, education level, occupation, oncological diagnosis, disease duration, and stage. Crude (RP) and adjusted (aRP

APA, Harvard, Vancouver, ISO, and other styles

18

Montuori, Eleonora, Caroline A. C. Hyde, Francesco Crea, Jon Golding, and Chiara Lauritano. "Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries." International Journal of Molecular Sciences 24, no. 2 (2023): 1435. http://dx.doi.org/10.3390/ijms24021435.

Full text

Abstract:

Prostate cancer is the most common cancer in men, with over 52,000 new cases diagnosed every year. Diagnostics and early treatment are potentially hindered by variations in screening protocols, still largely reliant on serum levels of acid phosphatase and prostate-specific antigen, with tumour diagnosis and grading relying on histopathological examination. Current treatment interventions vary in terms of efficacy, cost and severity of side effects, and relapse can be aggressive and resistant to the current standard of care. For these reasons, the scientific community is looking for new chemoth

APA, Harvard, Vancouver, ISO, and other styles

19

Snegovoy, A. V., V. B. Larionova, and I. B. Kononenko. "Differences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myeloma." Oncohematology 16, no. 1 (2021): 64–72. http://dx.doi.org/10.17650/1818-8346-2021-16-1-64-72.

Full text

Abstract:

Bone metastasis is one of the most common manifestations of advanced malignant process. Many tumors, especially breast, prostate and lung cancer, multiple myeloma, are characterized by a high incidence of bone damage (up to 7080 %) and clinical complications. Intense pain, hypercalcemia, spinal cord compression, pathological fractures, the need for radiation and surgical treatment (combined in the name «skeletal system related events») can occur even with single metastases. In the treatment of patients with bone metastases, a multidisciplinary approach is used; however, the basis is specific a

APA, Harvard, Vancouver, ISO, and other styles

20

Berardinelli, F., M. Iannucci, V. Verratti, W. Fusco, M. Nicolai, and R. L. Tenaglia. "Bisphosphonates Treatment in Metastatic Prostate Cancer." European Journal of Inflammation 3, no. 2 (2005): 49–54. http://dx.doi.org/10.1177/1721727x0500300201.

Full text

Abstract:

The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignancies that can cause destruction of skeletal bones include multiple myeloma and metastatic diseases of the lung, prostate and other solid cancers. The clinical complications include pain, fractures, compression of the spinal cord and hypercalcemia of malignancy. Bisphosphonates are bone-seeking agents originally designed to treat loss of bone density. Accumulating data show that they are effective in diseases in which there is upregulation of osteoclastic or osteolytic activity. Bisphosphonates ca

APA, Harvard, Vancouver, ISO, and other styles

21

Kang, Yubin, Xiaobei Wang, Jian Wu, et al. "Inhibition of Sphingosine Kinase 2 Enhances Immunotherapy in Mouse Model of Multiple Myeloma." Blood 142, Supplement 1 (2023): 876. http://dx.doi.org/10.1182/blood-2023-186965.

Full text

Abstract:

Introduction: Sphingolipid metabolism, in particular the ceramide:sphigosine 1-phophate (S1P) rheostat, is increasingly recognized as a key pathway in cancer biology, inflammation and immune responses. Sphingosine kinase (SK) 1 and 2 catalyze the formation of S1P. We previously reported that SK2 but not SK1 was overexpressed in multiple myeloma (MM) cells. Treatment with opaganib, an SK2-specific inhibitor, downregulated the expression of c-Myc and Mcl-1, resulting in apoptosis of MM cells. A phase I clinical trial of opaganib in patients with relapsed/refractory MM demonstrated the safety and

APA, Harvard, Vancouver, ISO, and other styles

22

Iqbal, Rashid, Shafi Rehman, Mahnoor Sukaina, Hameed Ullah, Maha Hameed, and Uzair Chattha. "A challenging diagnosis of rare co-existent multiple myeloma and prostate adenocarcinoma: a systematic review of case reports." Journal of the Pakistan Medical Association 73, no. 8 (2023): 1684–92. http://dx.doi.org/10.47391/jpma.8068.

Full text

Abstract:

Objective: To review biochemical parameters, clinical characteristics, demographics, radiological and histopathological findings, treatment modalities and outcomes used to examine patients with coexisting multiple myeloma and prostate adencocarcinoma. Method: The systematic review comprised search on PubMed, Google Scholar, Science Direct and the Directory of Open Access Journal databases for case reports published till June 1, 2022. The search was done in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using appropriate key words. Case reports inclu

APA, Harvard, Vancouver, ISO, and other styles

23

Piccolomo, Antonio, Claudia Pia Schifone, Vanda Strafella, Giorgina Specchia, Pellegrino Musto, and Francesco Albano. "Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment." Cancers 12, no. 9 (2020): 2528. http://dx.doi.org/10.3390/cancers12092528.

Full text

Abstract:

Immunomodulatory drugs (IMiDs) are analogs of thalidomide. They have immunomodulatory, antiangiogenic and proapoptotic properties and exert a role in regulating the tumor microenvironment. Recently IMiDs have been investigated for their pleiotropic properties and their therapeutic applications in both solid tumors (melanoma, prostate carcinoma and differentiated thyroid cancer) and hematological malignancies. Nowadays, they are applied in de novo and relapsed/refractory multiple myeloma, in myelodysplastic syndrome, in del5q syndrome with specific use of lenalidomide and B-cell lymphoma. Sever

APA, Harvard, Vancouver, ISO, and other styles

24

Rosenbloom, Barry E., Neal J. Weinreb, Ari Zimran, Katherine A. Kacena, Joel Charrow, and Elizabeth Ward. "Gaucher disease and cancer incidence: a study from the Gaucher Registry." Blood 105, no. 12 (2005): 4569–72. http://dx.doi.org/10.1182/blood-2004-12-4672.

Full text

Abstract:

Abstract Patients with Gaucher disease (GD) are alleged to be at an increased risk of malignant disorders, possibly due to potential chronic stimulation of the immune system and lymphoproliferation associated with storage of glucocerebroside in tissue macrophages. Because previous reports of increased risk of malignancy in GD may have been affected by small patient numbers and ascertainment bias, 2742 patients with GD from the International Gaucher Registry were studied. The number of cancers identified among patients in the registry was compared with that expected in the US population of simi

APA, Harvard, Vancouver, ISO, and other styles

25

Qaisar, Abdul Matin, Ghazanfar Ali Sirhindi, and Shamayal Mandokhel. "CANCER TYPES;." Professional Medical Journal 21, no. 01 (2018): 116–22. http://dx.doi.org/10.29309/tpmj/2014.21.01.1901.

Full text

Abstract:

Introduction: This study attempts to highlight the relation of various types ofcancers to abnormalities in liver and renal function tests. Objectives: Correlation of derangedrenal and liver function tests to different types of cancers in industrial workers who are exposed toindustrial chemicals and carcinogens. Patients and Methods: This non-interventional studyincluded 100 hundred confirmed cases of cancer were selected and studied from July 2011 toDecember 2011. The study was conducted at Fatima Memorial Hospital/College of Medicine &Dentistry, Lahore . Results: Out of these 100 patients

APA, Harvard, Vancouver, ISO, and other styles

26

Lamont, Elizabeth B., Andrew J. Yee, Stuart L. Goldberg, and Andrew D. Norden. "Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma." Blood 134, Supplement_1 (2019): 2193. http://dx.doi.org/10.1182/blood-2019-125407.

Full text

Abstract:

Background: Over the past 20 years, observational data from usual care clinical oncology settings has been leveraged to inform estimates of cancer treatment-associated benefits and risks among patients not treated on clinical trials. Increasing genomic testing to inform treatment decisions in usual care settings now meaningfully augments traditional observational data, positioning it to provide insights beyond clinical care into tumor biology. We studied patients with newly diagnosed multiple myeloma (MM), comparing cytogenetic test patterns according to history of prior malignancy. Methods: I

APA, Harvard, Vancouver, ISO, and other styles

27

Suvannasankha, Attaya, Colin Crean, Isaac Carrera Ochoa, G. David Roodman, and John Chirgwin. "PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease." Blood 132, Supplement 1 (2018): 4450. http://dx.doi.org/10.1182/blood-2018-99-115680.

Full text

Abstract:

Abstract Background: Cachexia, an energy-wasting disorder of adipose and skeletal muscles, occurs commonly in advanced cancers and is a serious problem that interferes with response to treatment and affects quality of life. Treatment or cachexia is yet available. Chemotherapy and radiation may further worsen cachexia. Cachexia in cancer bone metastasis was described in breast and prostate cancers where cancer cells induce osteolysis and systemic muscle wasting, with PTHrP secreted by tumor cells as a driver of the process. PTHrP increases RANKL-induced osteolysis and stimulates browning of whi

APA, Harvard, Vancouver, ISO, and other styles

28

Vlachostergios, Panagiotis J. "Endothelin Signaling as Target for Anticancer Therapy: from Prostate Cancer to Multiple Myeloma." Journal of Oncology and Cancer Research 2, no. 1 (2018): 1–3. http://dx.doi.org/10.28967/jocr.2018.01.18001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Parillo, Marco, and Carlo Augusto Mallio. "The Whole-Body MRI Reporting and Data System Guidelines for Prostate Cancer (MET-RADS-P), Multiple Myeloma (MY-RADS), and Cancer Screening (ONCO-RADS)." Cancers 17, no. 2 (2025): 275. https://doi.org/10.3390/cancers17020275.

Full text

Abstract:

Whole-body magnetic resonance imaging (WB-MRI) is being employed with increasing frequency to evaluate a broader spectrum of patients with diverse types of cancer and for cancer screening purposes. While clinical guidelines support its use, a standardized radiological approach is still lacking. To improve consistency in the acquisition, interpretation, and reporting of WB-MRI examinations, three reporting and data systems (RADSs) have been recently suggested: METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P), Myeloma Response Assessment and Diagnosis System (MY-RADS), and O

APA, Harvard, Vancouver, ISO, and other styles

30

Martins, Tanimola, Obioha C. Ukoumunne, Georgios Lyratzopoulos, Willie Hamilton, and Gary Abel. "Are There Ethnic Differences in Recorded Features among Patients Subsequently Diagnosed with Cancer? An English Longitudinal Data-Linked Study." Cancers 15, no. 12 (2023): 3100. http://dx.doi.org/10.3390/cancers15123100.

Full text

Abstract:

We investigated ethnic differences in the presenting features recorded in primary care before cancer diagnosis. Methods: English population-based cancer-registry-linked primary care data were analysed. We identified the coded features of six cancers (breast, lung, prostate, colorectal, oesophagogastric, and myeloma) in the year pre-diagnosis. Logistic regression models investigated ethnic differences in first-incident cancer features, adjusted for age, sex, smoking status, deprivation, and comorbidity. Results: Of 130,944 patients, 92% were White. In total, 188,487 incident features were recor

APA, Harvard, Vancouver, ISO, and other styles

31

Kumar, A., A. Mhaskar, S. Vadaparampil, B. Djulbegovic, and G. Quinn. "Fertility preservation and timing of cancer treatment." Journal of Clinical Oncology 27, no. 15_suppl (2009): e20629-e20629. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20629.

Full text

Abstract:

e20629 Background: Cancer survival rates have increased steadily over time and young cancer survivors desire quality of life, including the ability to have a family. Cancer treatments, due to its toxic nature, can permanently or temporarily affect fertility. However, advanced fertility preservation measures are available and should be pursued before toxic chemo or radiation therapy. Evidence from observational studies indicate patients want to be informed of the adverse effects of cancer treatments on their fertility. Despite conflicting evidence on the efficacy of early treatment, the urgency

APA, Harvard, Vancouver, ISO, and other styles

32

Rand, Kristin A., Chi Song, Amie E. Hwang, et al. "Genetic Susceptibility Markers of Multiple Myeloma in African-Americans." Blood 124, no. 21 (2014): 2030. http://dx.doi.org/10.1182/blood.v124.21.2030.2030.

Full text

Abstract:

Abstract Multiple myeloma (MM) is 2-3 times more common among African-Americans compared to non-Hispanic whites. The 2-3-fold increased risk among family members of cases suggests a genetic contribution to risk. Genome-wide association studies (GWAS) in populations of European ancestry have identified seven novel risk loci at 2p23.3 (rs6746082), 3q26.2 (rs10936599), 3p22.1 (rs1052501), 6p21.32 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077) and 22q13.1 (rs877529) (Broderick, et al. Nat Genet, 2011, Chubb, et al. Nat Genet, 2013), three of which were replicated in another European series (

APA, Harvard, Vancouver, ISO, and other styles

33

Chen, Heyu, Yuanzhi Chen, Mi Deng, et al. "Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells." Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000515. http://dx.doi.org/10.1136/jitc-2019-000515.

Full text

Abstract:

BackgroundCurrent immune checkpoint blockade strategies have been successful in treating certain types of solid cancer. However, checkpoint blockade monotherapies have not been successful against most hematological malignancies including multiple myeloma and leukemia. There is an urgent need to identify new targets for development of cancer immunotherapy. LILRB1, an immunoreceptor tyrosine-based inhibitory motif-containing receptor, is widely expressed on human immune cells, including B cells, monocytes and macrophages, dendritic cells and subsets of natural killer (NK) cells and T cells. The

APA, Harvard, Vancouver, ISO, and other styles

34

Pan, Qingqing, Yaping Luo, Yanru Ma, and Fang Li. "The Change of 68Ga–Prostate-Specific Membrane Antigen Uptake in Myeloma After Chemotherapy in a Patient With Multiple Myeloma and Concurrent Prostate Cancer." Clinical Nuclear Medicine 45, no. 12 (2020): 1013–15. http://dx.doi.org/10.1097/rlu.0000000000003339.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Bloomfield, D. J. "Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review." Journal of Clinical Oncology 16, no. 3 (1998): 1218–25. http://dx.doi.org/10.1200/jco.1998.16.3.1218.

Full text

Abstract:

PURPOSE To review objectively the evidence for the use of bisphosphonates for the reduction of skeletal events or the management of pain due to multiple myeloma or bone metastases from other types of cancer. METHODS MEDLINE was searched from 1976 onwards using the MeSH terms "exp diphosphonates/," "exp bone neoplasms/," "exp multiple myeloma/," and "bone metastases" as text words. Bibliographies of reports on these topics and major medical and scientific journals were searched. Experts in the field were approached. The question was defined and the evidence stratified in a hierarchical manner a

APA, Harvard, Vancouver, ISO, and other styles

36

Guo, Ying, An Thuy Ngo-Huang, and Jack B. Fu. "Perspectives on Spinal Precautions in Patients Who Have Cancer and Spinal Metastasis." Physical Therapy 100, no. 3 (2020): 554–63. http://dx.doi.org/10.1093/ptj/pzz178.

Full text

Abstract:

Abstract Bones are the third most common site for cancer metastases, and the axial skeleton is the most frequent skeletal location. In a postmortem study, bone metastases were reported in 70% of breast and prostate cancer patients. Bone metastases from breast, lung, prostate, thyroid, and kidney cancers account for 80% of all bone metastases. Bone lesions exist in 60% of newly diagnosed multiple myeloma patients. With increasing numbers of people who have survived cancer, many patients with cancer and axial skeletal bony metastases will be seen by physical and occupational therapists. Guidelin

APA, Harvard, Vancouver, ISO, and other styles

37

Westhrin, Marita, Siv Helen Moen, Toril Holien, et al. "GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease." Blood 124, no. 21 (2014): 2065. http://dx.doi.org/10.1182/blood.v124.21.2065.2065.

Full text

Abstract:

Abstract Introduction Growth differentiation factor 15 (GDF15) is a multifunctional growth factor of the transforming growth factor beta (TGFbeta) family that plays a complex role in several types of cancers. In multiple myeloma, GDF15 was recently shown to enhance the tumor-initiating and self-renewal potential of the cancer cells (Tanno et al, Blood 2014). Moreover, blood and bone marrow plasma levels of GDF15 are elevated in myeloma patients compared with healthy persons, and high serum levels are associated with a poor prognosis (Corre et al, Cancer Research 2012). GDF15 seems important fo

APA, Harvard, Vancouver, ISO, and other styles

38

Basanta, David, Conor Lynch, Anna Miller, and Ryan Bishop. "Abstract A028: Selective pressures on bone cancer evolution and treatment resistance emerging from the interactions with the bone ecosystem." Cancer Research 82, no. 10_Supplement (2022): A028. http://dx.doi.org/10.1158/1538-7445.evodyn22-a028.

Full text

Abstract:

Abstract The bone is the organ of origin of several types of cancer including multiple myeloma, as well as a host to many metastatic lesions such as those characterizing prostate and breast cancer. The evolutionary dynamics that drive primary and metastatic progression in the bone, as well as those that explain the emergence of resistance to treatments such as proteosome inhibitors and hormonal deprivation therapies, result from the interactions between the tumor and the bone ecosystem. Models that can capture the complex ecological interactions in the bone are key to define the selective pres

APA, Harvard, Vancouver, ISO, and other styles

39

Yu, Hui-I., Hui-Ching Shen, Shu-Hsin Chen, et al. "Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine Treatment." International Journal of Molecular Sciences 20, no. 21 (2019): 5315. http://dx.doi.org/10.3390/ijms20215315.

Full text

Abstract:

Aloperine, an alkaloid isolated from Sophora alopecuroides, exhibits multiple pharmacological activities including anti-inflammatory, antioxidant, antiallergic, antinociceptive, antipathogenic, and antitumor effects. Furthermore, it exerts protective effects against renal and neuronal injuries. Several studies have reported antitumor effects of aloperine against various human cancers, including multiple myeloma; colon, breast, and prostate cancers; and osteosarcoma. Cell cycle arrest, apoptosis induction, and tumorigenesis suppression have been demonstrated following aloperine treatment. In a

APA, Harvard, Vancouver, ISO, and other styles

40

Santos, J., R. Palacios, J. Ruiz, M. González, and M. Márquez. "Unusual malignant tumours in patients with HIV infection." International Journal of STD & AIDS 13, no. 10 (2002): 674–76. http://dx.doi.org/10.1258/095646202760326417.

Full text

Abstract:

The clinical charts of 2560 HIV-infected patients seen in our Unit between 01/89 and 08/01 were reviewed. All patients with a neoplasm were analysed to study the prevalence of tumours other than Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL) or cancer of the cervix. There were 43 unusual malignant tumours: 13 lung cancers, six leukaemias, six skin cancers, two carcinomas of the conjunctiva, two cancers of the penis, three of the anus, three of the larynx, one sarcoma of the ureter, one gastric carcinoid, one non-differentiated thyroid carcinoma, one non-differentiated prostate carcinoma,

APA, Harvard, Vancouver, ISO, and other styles

41

D'Souza, Sonia, Noriyoshi Kurihara, Yusuke Shiozawa, Russell Taichman, Deborah Galson, and David Roodman. "Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment." Blood 116, no. 21 (2010): 130. http://dx.doi.org/10.1182/blood.v116.21.130.130.

Full text

Abstract:

Abstract Abstract 130 Multiple myeloma (MM) is an incurable B-cell malignancy that develops in the bone marrow. The marrow microenvironment plays a critical role in supporting homing, lodging, and growth of MM cells by activating signaling pathways in both MM and bone marrow stromal cells (BMSC). Recently, we identified that annexin II (AXII) is involved in prostate cancer cell lodgment to the bone marrow as well as mobilization of prostate cancer cells to the peripheral blood. AXII expressed on stromal cells supports prostate cancer cell lodgment via the annexin II receptor (AXIIR) on prostat

APA, Harvard, Vancouver, ISO, and other styles

42

Siveen, Kodappully S., Parveen B. Nizamuddin, Shahab Uddin, et al. "TRPV2: A Cancer Biomarker and Potential Therapeutic Target." Disease Markers 2020 (December 10, 2020): 1–10. http://dx.doi.org/10.1155/2020/8892312.

Full text

Abstract:

The Transient Receptor Potential Vanilloid type-2 (TRPV2) channel exhibits oncogenicity in different types of cancers. TRPV2 is implicated in signaling pathways that mediate cell survival, proliferation, and metastasis. In leukemia and bladder cancer, the oncogenic activity of TRPV2 was linked to alteration of its expression profile. In multiple myeloma patients, TRPV2 overexpression correlated with bone tissue damage and poor prognosis. In prostate cancer, TRPV2 overexpression was associated with the castration-resistant phenotype and metastasis. Loss or inactivation of TRPV2 promoted gliobla

APA, Harvard, Vancouver, ISO, and other styles

43

Larbi, A., P. Omoumi, V. Pasoglou, et al. "Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI." Diagnostic and Interventional Imaging 100, no. 5 (2019): 295–302. http://dx.doi.org/10.1016/j.diii.2018.12.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Sučić, Mirna, Vesna Bišof, Mirjana Čačić, et al. "A patient with prostate cancer and multiple myeloma—diagnostics and possible association of both diseases." Annals of Diagnostic Pathology 16, no. 6 (2012): 515–20. http://dx.doi.org/10.1016/j.anndiagpath.2011.04.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Gifkins, Dina, Megan McAuliffe, Amy Matcho, et al. "Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,." Blood 118, no. 21 (2011): 3972. http://dx.doi.org/10.1182/blood.v118.21.3972.3972.

Full text

Abstract:

Abstract Abstract 3972 Second hematologic malignancies have been found to occur at a higher rate among multiple myeloma patients compared to the general population. Although alkylating therapy has been suggested to play a role, the underlying causes remain largely unclear. Increased survival benefit has been documented with the introduction of novel agents over the past decade, and, as noted in other cancers, there may also be a higher occurrence of second malignancies in the era of novel therapies. Recently, data from Phase III studies suggest that patients treated with lenalidomide with prio

APA, Harvard, Vancouver, ISO, and other styles

46

Annibali, Ombretta, Maria Teresa Petrucci, Daniele Santini, et al. "Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions." Blood 126, no. 23 (2015): 5359. http://dx.doi.org/10.1182/blood.v126.23.5359.5359.

Full text

Abstract:

Abstract Background: alkaline phosphatase (ALP) is an enzyme localized in different tissues and its levels may increase in diseases with skeletal involvement. Aim: To compare ALP levels in patients with Multiple Myeloma and osteolytic lesions, and in patients with solid tumors (breast, prostate, lung, stomach, kidney and colon) and osteolytic, osteoblastic and mixed (osteolytic and osteoblastic) bone metastatic lesions. Patients and Methods: From 1991 we collected 400 patients with MM and 308 patients with solid cancer with bone involvement. We grouped patients according to the metastases type

APA, Harvard, Vancouver, ISO, and other styles

47

Ezennia, Somayina C., Christine G. Parks, Laura E. Beane Freeman, et al. "Abstract 6220: Disparities in cancer incidence among African American and non-Hispanic white participants in the Agricultural Health Study and North Carolina residents." Cancer Research 85, no. 8_Supplement_1 (2025): 6220. https://doi.org/10.1158/1538-7445.am2025-6220.

Full text

Abstract:

Abstract Disparities in cancer incidence between African American (AA) and non-Hispanic white (NHW) populations in the U.S. are well documented. However, no studies have examined cancer incidence disparities in farming populations. Given unique occupational hazards (e.g., pesticides, zoonotic diseases, diesel exhaust), we hypothesized that racial disparities in cancer incidence may be more pronounced among AA farmers than in the general population. We investigated cancer incidence among North Carolina (NC) participants in Agricultural Health Study (AHS), a prospective cohort of pesticide appli

APA, Harvard, Vancouver, ISO, and other styles

48

Hofmann, Jonathan N., Linda M. Liao, Michael N. Pollak, et al. "A prospective study of circulating adipokine levels and risk of multiple myeloma." Blood 120, no. 22 (2012): 4418–20. http://dx.doi.org/10.1182/blood-2012-06-438606.

Full text

Abstract:

Abstract It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese persons could be the result of altered circulating levels of adipokines, polypeptide hormones with pro- and anti-inflammatory properties secreted by adipose tissue. We investigated whether circulating levels of leptin, total adiponectin, and high molecular weight adiponectin are associated with subsequent MM risk among 174 MM patients and 348 controls within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Inverse associations with MM were observed for total adiponectin (high

APA, Harvard, Vancouver, ISO, and other styles

49

Rugani, Petra, Christian Walter, Barbara Kirnbauer, Stephan Acham, Yvonne Begus-Nahrman, and Norbert Jakse. "Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma." Dentistry Journal 4, no. 4 (2016): 32. http://dx.doi.org/10.3390/dj4040032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Stultz, Jacob, and Lawrence Fong. "How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer." Prostate Cancer and Prostatic Diseases 24, no. 3 (2021): 697–717. http://dx.doi.org/10.1038/s41391-021-00340-5.

Full text

Abstract:

Abstract Background Advanced prostate cancer remains one of the most common and deadly cancers, despite advances in treatment options. Immunotherapy has provided little benefit to a majority of patients, largely due to the immunosuppressive tumor microenvironment that gives rise to inherently “cold tumors”. In this review, we discuss the immunopathology of the prostate tumor microenvironment, strategies for treating prostate cancer with immunotherapies, and a perspective on potential approaches to enhancing the efficacy of immunotherapies. Methods Databases, including PubMed, Google Scholar, a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!